News and Views
Persistent Underperformance Against Benchmarks
Vivanza Biosciences has been grappling with a challenging market environment, as evidenced by its returns relative to the Sensex. Over the past week, the stock has declined by 7.91%, while the Sensex managed a modest gain of 0.31%. This negative divergence extends over longer periods, with the stock falling 9.59% in the last month compared to the Sensex’s 2.51% decline. Year-to-date, Vivanza Biosciences has lost 10.00%, significantly underperforming the Sensex’s 3.11% drop.
The disparity becomes even more pronounced over the one-year and multi-year horizons. The stock has plummeted 35.08% in the past year, whereas the Sensex has appreciated by 7.88%. Over three and five years, the stock’s losses have been severe at 86.42% ...
Read full news article
